STUDY: FIRST TIME STROKE SURVIVORS HAVE SUBSTANTIAL IMMEDIATE AND ACCELERATED LONG TERM-COGNITIVE DECLINE New evidence points to vascular risk factors exerting impact on cognitive function years before stroke onset
SEGMENT
Filmed in Sydney | January 2025
New evidence from the Centre for Healthy Brain Ageing (CHeBA) indicates that older adults who experience a stroke for the first time will have substantial immediate and accelerated long term-cognitive decline.
Stroke is a leading cause of disability and dementia globally, with projections indicating a continued rise in both prevalence and burden. The new research, published in October 2024 in JAMA Network Open, looked at finding out exactly how a stroke impacts a person’s cognitive abilities.
Stroke occurs when blood flow to part of the brain is blocked or reduced, causing damage to brain cells. Previous research from the Centre has shown that more than a third of stroke survivors’ ability to think, remember and make decisions is significantly disadvantaged after stroke, with clear deficits in cognition or vascular dementia present.
Vascular dementia, the second most common type of dementia, is caused by reduced blood flow to the brain. The research, led by biostatistician and Research Associate Jess Lo, addressed many unanswered questions about this dementia type, which is yet to be studied as extensively as Alzheimer’s disease.
“Although we do experience changes to our brain functioning over time and as we age, certain medical conditions can potentially speed up these changes, which may lead to cognitive impairment or dementia,” says Lo.
The research analysed data from 14 studies that followed community dwelling older adults without a history of stroke or dementia, with an average age of 73 over many years, tracking their health and cognitive abilities. The studies, part of the CHeBA-led international Cohort Studies of Memory in an International Consortium (COSMIC), span 11 countries including Australia, Brazil, France and the US.
With data from 20,860 participants, the researchers identified people who experienced their first stroke during the study period.
The research also found that individuals who had a history of diabetes, hypertension, high cholesterol, cardiovascular disease, depression, smoked or were APOE4 carriers exhibited significantly faster cognitive decline before any stroke.
Senior author on the paper and Co-Director of the Centre for Healthy Brain Ageing (CHeBA), Professor Perminder Sachdev, said that this global collaborative study highlights the significant and lasting negative impact of stroke on brain cognition.
“Our findings can help clinicians better plan for the ongoing needs of stroke survivors who are at risk of disability and a lower quality of life,” said Professor Sachdev.
You Might also like
-
Contrasting Population Needs and Alternative Funding Models
Dr Jaspreet Saini is a GP with a decade of experience, practicing in West Pennant Hills and Rooty Hill, New South Wales. He began his medical journey at Monash University, followed by internships and residency at Blacktown Hospital, in Western Sydney. Instead of confining himself to a single specialty, he pursued general practice to explore various facets of medicine.
-
A 40-Year Journey: Insights from Tasmania’s Chief Nurse & Midwife
Reflecting on her nursing journey on the Tasmanian Health website on International Nurses Day 2025, Chief Nurse and Midwife, Francine Douce, has seen plenty of change since the start of her nursing and midwifery career, 42 years ago.
-
Significant funding announced for NSW biomedical researchers
The Snow Medical Research Foundation (Snow Medical) has announced a new $24 million investment in three outstanding Australian biomedical researchers through its prestigious Snow Fellowships.
These Fellows will tackle major global health challenges spanning autoimmune disease, neurological disorders, and genetic disease. Their work addresses conditions that disproportionately affect vulnerable and underserved populations, including First Nations communities, while advancing precision medicine and translational care. Collectively, their research aims to deliver safer vaccines, better diagnostics, and more equitable genomic and neurological healthcare.